SCHEMBL6444679

SCHEMBL6444679

S=C(Cc1ccc(Oc2ccc(Cl)cc2)cc1)N1CCOCC1

nearest known ligand 0.83

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.83
MGLL Q99685 5/20 0.83
FAAH O00519 3/20 0.83
HPGD P15428 4/20 0.68
MAPT P10636 2/20 0.68
GAA P10253 1/20 0.68
APOBEC3G Q9HC16 1/20 0.68
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
CYP2C19 P33261 1/20 0.53
PHGDH O43175 2/20 0.51
TSHR P16473 1/20 0.51
HSD17B10 Q99714 1/20 0.51
USP2 O75604 1/20 0.47
AKR1C3 P42330 1/20 0.47
LMNA P02545 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4399380 0.91 ALDH1A1 (1.00) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL6380824 0.87 MGLL (0.72) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL5924440 0.86 ALDH1A1 (0.68) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL4394405 0.81 ALDH1A1 (1.00) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL6578765 0.81 FAAH (0.62) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL4397261 0.76 ALDH1A1 (1.00) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL1108678 0.76 MGLL (0.82) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL9529297 0.76 ALDH1A1 (0.71) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL11564701 0.74 MGLL (0.56) ALDH1A1MGLLFAAHHPGDMAPT
SCHEMBL12590360 0.74 ALDH1A1 (0.72) ALDH1A1MGLLFAAHHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1226128-B1 NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS HOFFMANN LA ROCHE (CH) 2005-02-23 EP disclosed
US-6716845-B2 Barbituric acid derivatives HOFFMANN-LA ROCHE INC. 2004-04-06 US disclosed
EP-1383746-A2 NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2004-01-28 EP disclosed
US-6498252-B1 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds HOFFMANN-LA ROCHE INC. 2002-12-24 US disclosed
US-20020187991-A1 Barbituric acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 US disclosed
WO-2002079170-A2 PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THEM F. HOFFMANN-LA ROCHE AG (CH) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020187991-A1 Barbituric acid derivatives GABBR1, GABBR2, TUBB6 ALDH1A1 159/4885MGLL 4796/4885FAAH 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.